{
    "clinical_study": {
        "@rank": "6734", 
        "arm_group": {
            "arm_group_label": "DI-Leu16-IL2", 
            "arm_group_type": "Experimental", 
            "description": "Patients will receive DI-Leu16-IL2 at the same assigned dose level, dosing schedule, and route of administration that they received during the parent clinical trial AO-101. Patients may continue to receive therapy through the duration of the study as long as they are having clinical benefit and not experiencing any untoward side effects."
        }, 
        "brief_summary": {
            "textblock": "An open-label extension study enrolling patients experiencing clinical benefit following 6\n      cycles of DI-Leu16-IL2 while enrolled in the Alopexx Oncology AO-101 study.  Patients will\n      be permitted to continue to receive DI-Leu16-IL2 at the same dose, schedule, and route of\n      administration they received while on the parent protocol. Prior pre-treatment (e.g.\n      Rituximab) will continue as before."
        }, 
        "brief_title": "An Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Patients With B-cell Non-Hodgkin Lymphoma (NHL)", 
        "completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "B-cell Non-Hodgkin Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Lymphoma, B-Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "1. Primary Endpoints:\n\n           \u2022 To continue to provide DI-Leu16-IL2 to patients currently enrolled in Alopexx\n           Oncology trial AO-101 who are experiencing clinical benefit.\n\n        2. Secondary Endpoints:\n\n             -  To continue to evaluate the safety of DI-Leu16-IL2."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients currently entered on Alopexx Oncology Protocol AO-101\n\n          2. Patient has received 6 cycles of DI-Leu16-IL2 on Protocol AO-101\n\n          3. Documented clinical benefit following 6th cycle of DI-Leu16-IL2.\n\n          4. Able to begin extension study within 8 weeks of receiving 6th cycle of DI-Leu16-IL2\n\n          5. Patients must have received prior Rituximab-containing therapy.\n\n          6. Patients participating in the study are to use adequate birth control measures\n             (abstinence, oral contraceptives, barrier method with spermicide or surgical\n             sterilization) during study participation.  Females of childbearing potential must\n             have a negative serum pregnancy test on the days of dosing. A female of childbearing\n             potential is a sexually mature woman who: 1) has not undergone a hysterectomy or\n             bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24\n             consecutive months (i.e., has had menses at any time in the preceding 24 consecutive\n             months.\n\n          7. Provide written informed consent prior to any study procedures.\n\n        Exclusion Criteria:\n\n          1. Pregnant or lactating female.\n\n          2. An immediate need for palliative radiotherapy or systemic corticosteroid therapy.\n\n          3. Actively infected with or chronic carriers of hepatitis B virus (HBV) as demonstrated\n             by positive hepatitis B core antibody (HbcAb) or hepatitis B surface antigen (HbsAg).\n             (Patients who are sero-positive only, i.e., surface antibody positive [HbsAb], are\n             permitted).\n\n          4. Other significant active infection.\n\n          5. Major surgery, chemotherapy, investigational agent, or radiation within 30 days of\n             Day 1.\n\n          6. Uncontrolled hypertension (diastolic \u2265 100 mmHg) or hypotension (systolic \u2264 90 mmHg).\n\n          7. History of prior therapy or a serious, uncontrolled medical disorder that in the\n             Investigator's opinion would impair participation in the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "66", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02151903", 
            "org_study_id": "AO-101-EXT"
        }, 
        "intervention": {
            "arm_group_label": "DI-Leu16-IL2", 
            "intervention_name": "DI-Leu16-IL2", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Interleukin-2"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "NHL", 
            "Immunocytokine", 
            "Lymphoma", 
            "Non-Hodgkin", 
            "B-cell", 
            "IL (interleukin)"
        ], 
        "lastchanged_date": "May 28, 2014", 
        "link": [
            {
                "description": "Sponsor website", 
                "url": "http://www.alopexx.com"
            }, 
            {
                "description": "National Cancer Institute at the National Institute of Health", 
                "url": "http://www.cancer.gov/cancertopics/types/non-hodgkin"
            }
        ], 
        "location": [
            {
                "contact": {
                    "email": "rnakamura@coh.org", 
                    "last_name": "Ryotaro Nakamura, MD", 
                    "phone": "626-256-4673"
                }, 
                "facility": {
                    "address": {
                        "city": "Duarte", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91010"
                    }, 
                    "name": "City of Hope"
                }, 
                "investigator": {
                    "last_name": "Ryotaro Nakamura, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "bach0173@umn.edu", 
                    "last_name": "Veronika Bachanova, M.D.", 
                    "phone": "612-625-5469"
                }, 
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55455"
                    }, 
                    "name": "University of Minnesota"
                }, 
                "investigator": {
                    "last_name": "Veronika Bachanova, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "frederick.lansigan@hitchcock.org", 
                    "last_name": "Fredrick Lansigan, MD", 
                    "phone": "603-650-5529"
                }, 
                "facility": {
                    "address": {
                        "city": "Lebanon", 
                        "country": "United States", 
                        "state": "New Hampshire", 
                        "zip": "03756"
                    }, 
                    "name": "Dartmouth-Hitchcock Medical Center"
                }, 
                "investigator": {
                    "last_name": "Frederick Lansigan, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Patients With B-cell NHL", 
        "overall_contact": {
            "email": "michelle.nelken@alopexx.com", 
            "last_name": "Michelle Nelken", 
            "phone": "617-755-4149"
        }, 
        "overall_official": {
            "affiliation": "Alopexx Oncology, LLC", 
            "last_name": "Daniel Vlock, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board", 
                "United States: Data and Safety Monitoring Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Tumor measurements will be performed by radiologic imaging techniques at every other monthly visit.  The International Workshop for NHL Response Criteria will be used to evaluate the response.", 
            "measure": "Tumor response in patients", 
            "safety_issue": "No", 
            "time_frame": "up to 12 months"
        }, 
        "reference": [
            {
                "PMID": "15076141", 
                "citation": "Ko YJ, Bubley GJ, Weber R, Redfern C, Gold DP, Finke L, Kovar A, Dahl T, Gillies SD. Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer. J Immunother. 2004 May-Jun;27(3):232-9."
            }, 
            {
                "PMID": "15483010", 
                "citation": "King DM, Albertini MR, Schalch H, Hank JA, Gan J, Surfus J, Mahvi D, Schiller JH, Warner T, Kim K, Eickhoff J, Kendra K, Reisfeld R, Gillies SD, Sondel P. Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J Clin Oncol. 2004 Nov 15;22(22):4463-73. Epub 2004 Oct 13."
            }, 
            {
                "PMID": "7522629", 
                "citation": "Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, Levy R. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994 Oct 15;84(8):2457-66."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02151903"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Safety assessment in patients monitoring adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 12 months"
            }, 
            {
                "measure": "Safety assessment in patients monitoring clinical laboratory tests", 
                "safety_issue": "Yes", 
                "time_frame": "up to 12 months"
            }, 
            {
                "measure": "Safety assessment in patients monitoring physical exams", 
                "safety_issue": "Yes", 
                "time_frame": "up to 12 months"
            }
        ], 
        "source": "Alopexx Oncology, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alopexx Oncology, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}